8 results about "Established diagnosis" patented technology

The invention provides a method for establishing a diagnosis and treatment system for digestive system disease multi-modal information. The method comprises the following steps: S1, collecting multi-modal information for labeling and preprocessing; s2, extracting a feature vector and embedding a label into the multi-modal information according to the labeled information; s3, splicing and mapping the feature vector and the tag to a unified dimension to obtain an enhanced feature vector; s4, fusing the enhanced feature vectors to form a multi-modal feature matrix, performing linear mapping and weighted aggregation on the multi-modal feature matrix to obtain global fusion vectors, and collecting to generate a fusion vector sequence; s5, enhancing the time sequence information of the global fusion vector sequence, enhancing the spatial information of the spatial relevance of the specific feature of the part, and performing interactive fusion to obtain a spatio-temporal joint feature; s6, performing classification prediction on the disease stage or the specific pathological type, and outputting a diagnosis result; and S7, performing semantic association on the diagnosis result and the medical knowledge graph, sharing data to an online health intelligent platform, and providing a personalized decision basis for clinicians.

The invention discloses a marker combination and application thereof in diagnosis of expression metaplasia of spasmolysis polypeptide. The marker combination comprises an SCD1 marker combination, a PHB1 marker combination and a p-ERK marker combination. The marker combination is based on joint detection of SCD1, PHB1 and p-ERK markers, the sensitivity and the specificity of an established diagnosis model are remarkably superior to those of a traditional single detection method, and early recognition of the potential precancerous lesion SPEM is facilitated.

The invention relates to the technical field of molecular diagnosis and early screening of tumors, and particularly discloses a plasma circulating microbial marker for early screening of lung cancer and application of the plasma circulating microbial marker. The marker comprises the following components: staphylococcus aureus, fusobacterium nucleatum, klebsiella pneumoniae, alternaria simplex, legionella pneumophila, neisseria mucosa, Ralstonia petii, pasteurella multocida, and haemophilus parainfluenza (Haemophilus parainfluenza), and the marker comprises the following components: staphylococcus aureus, fusobacterium nucleatum, klebsiella pneumoniae, alternaria simplex, legionella pneumophila, neisseria mucosa, Ralstonia petii, pasteurella multocida, and Haemophilus parainfluenza (Haemophilus parainfluenza). According to the method, nine characteristic microbial markers are detected in combination with a low Pass WGS technology, a high-precision diagnosis model is constructed through a machine learning algorithm, the established diagnosis model has excellent stability and clinical applicability, efficient recognition of early lung cancer can be achieved, and the detection cost can be greatly reduced.

The present application relates to the field of medical informatization and artificial intelligence technology, and specifically provides a medical record connotation quality control method and device based on a large language model, which has the following steps: S1, medical record document data access, document content preprocessing; S2, clear quality control content, construct quality control rule library; S3, construct medical knowledge base: based on clinical guidelines and evidence-based medicine evidence base, establish diagnosis standard, drug, treatment project, inspection project knowledge base; S4, entity extraction: use a large language model to extract diagnosis, drug, treatment project and inspection project name; S5, model reasoning: query the relevant information of the extracted entity in the knowledge base, according to the quality control rules, combine the queried relevant information with the medical document and submit them to the large model for reasoning to give the quality control result; S6, problem collection, model optimization. Compared with the prior art, the present application can significantly improve the intelligent level of medical record connotation quality control, effectively assist clinical doctors and quality control personnel to improve the quality of medical record writing, ensure medical safety, and improve hospital management efficiency.

A method for the in vitro diagnosis of the risk of delayed cerebral ischemia (DCI) following subarachnoid hemorrhage from a ruptured aneurysm (aSAH) which includes the following steps: collection of a blood sample from the patient; quantitative determination of 8-iso-prostaglandin F2α (F2-IsoP) concentration in plasma; comparison of the concentration thereof in plasma with the reference value; collection of at least one further blood sample; quantitative determination of the concentration of endothelial nitric oxide synthase (eNOS) and / or nicotinamide adenine dinucleotide phosphate (NADPH) in plasma; comparison of the concentration thereof in plasma with the reference value; analysis of the obtained results and establishing diagnosis. A marker substance for the in vitro diagnosis of the risk of occurrence of DCI selected from 8-iso-prostaglandin F2α (F2-IsoP), endothelial nitric oxide synthase (eNOS), nicotinamide adenine dinucleotide phosphate (NADPH) and combinations thereof and the use thereof as a screening test for the in vitro diagnosis of DCI following aSAH.

The application relates to a flow meter calibration method, device, computer equipment and storage medium, which comprises the following steps: acquiring characteristic data of a target flow meter, wherein the characteristic data comprises acceleration and flow value of the target flow meter; determining whether the state of the target flow meter is abnormal according to the characteristic data; if the state of the target flow meter is abnormal, determining a diagnosis parameter of the target flow meter according to the characteristic data; and searching for an abnormal reason corresponding to the diagnosis parameter in a pre-established diagnosis database according to the diagnosis parameter, wherein the diagnosis database comprises a mapping relationship between diagnosis parameters and abnormal reasons of a template flow meter. The above method can monitor and record abnormal vibration data of the target flow meter in real time, and can diagnose the reason for the abnormal vibration of the target flow meter in a timely manner.

The invention discloses application of linoleic acid as a biomarker and a kit for detecting the biomarker, and belongs to the technical field of medical detection. According to the model, the biomarker content level serves as an input variable, a diagnosis model is constructed, the biomarker is linoleic acid, and the model use equation is as follows: score = 2.09 * linoleic acid content level / 1000-9.399. Among coronary heart disease groups, linoleic acid in patients with hyperlipemia is obviously higher than linoleic acid in non-hyperlipemia groups, the established diagnosis model has good sensitivity and specificity, and the provided kit can realize diagnosis and prognosis monitoring of hyperlipemia and can guide lipid nutrition intake of patients in the treatment process.

A method for the in vitro diagnosis of the risk of delayed cerebral ischemia (DCI) following subarachnoid hemorrhage from a ruptured aneurysm (aSAH) which includes the following steps: collection of a blood sample from the patient; quantitative determination of 8-iso-prostaglandin F2α (F2-IsoP) concentration in plasma; comparison of the concentration thereof in plasma with the reference value; collection of at least one further blood sample; quantitative determination of the concentration of endothelial nitric oxide synthase (eNOS) and / or nicotinamide adenine dinucleotide phosphate (NADPH) in plasma; comparison of the concentration thereof in plasma with the reference value; analysis of the obtained results and establishing diagnosis. A marker substance for the in vitro diagnosis of the risk of occurrence of DCI selected from 8-iso-prostaglandin F2α (F2-IsoP), endothelial nitric oxide synthase (eNOS), nicotinamide adenine dinucleotide phosphate (NADPH) and combinations thereof and the use thereof as a screening test for the in vitro diagnosis of DCI following aSAH.